MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update

MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update




MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update

Conference Call on Thursday, November 3rd, 2022, at 8:30 a.m. ET

NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced it will release its third quarter 2022 financial results before the market opens on Thursday, November 3rd, 2022. MiNK leadership will host a conference call and webcast at 8:30 a.m. ET that same day.

Conference Call:

Dial-in numbers: 646-307-1952 (United States); 888-672-2415 (USA & Canada)

Event ID: 3583551

Webcast:

A webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/9f7m9syw

About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/.

Contact
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com